Delivering unique monoclonal antibodies against membrane receptors and haptens

SYnAbs' mission is to generate innovative antibodies against

poor immunogenic compounds &

complex transmembrane antigens.

Either as a custom service,

or as a catalog product,

you can benefit

from SYnAbs technologies

to get access to

singular monoclonal antibodies.

Click to discover SYnAbs unique SECONDARY monoclonal antibodies products OFF-THE-SHELF CATALOGUE

Click to discover SYnAbs unique PRIMARY monoclonal antibodies products OFF-THE-SHELF CATALOGUE

Click to learn more about custom antibody generation at SYnAbs YOUR SPECIFIC MONOCLONAL ANTIBODY PROJECT

Raising antibodies against difficult to express antigens

Generating antibodies against conformation sensitive targets thanks to proprietary DNA and whole cell immunization technologies

>99% success rate for small, difficult and poor immunogenic antigens

Extreme specificity monoclonal antibodies

Higher affinity monoclonal antibodies

Access to multiple immune repertoires

Additional epitope recognition

Time to enjoy your free ebook :

"Proven strategies for successful antibodies generation against difficult antigens"

Click to discover SYnAbs unique PRIMARY monoclonal antibodies products SYNABS OFF-THE-SHELF CATALOGUE

Click to discover SYnAbs unique SECONDARY monoclonal antibodies products SYNABS OFF-THE-SHELF CATALOGUE

Click to learn more about custom antibody generation at SYnAbs YOUR SPECIFIC MONOCLONAL ANTIBODY PROJECT

Where to meet SYnAbs in 2021?

March 2nd - March 5th

March 9th - March 12th

March 22nd - March 25th

March 29th - April 1st

April 15th - April 16th

May 6th - May 7th

June 14th - June 18th

Sept 13th - Sept 19th

Sept 20th - Sept 24th

Sept 28th

Oct 13th - Oct 15th

Oct 25th - Oct 27th

Nov 15th - Nov 18th

Dec 7th - Dec 9th

Dec 10th

Oncology Virtual Partnering

Immunology Virtual Partnering

BioEurope Spring

Festival of Biologics

Innovation for Health

Meet2Win

BIO International Convention

Dr. GPCR Summit

Life Science Baltics

Knowledge for Growth

BioJapan

BioEurope Fall

Medica

BioFIT

BioWin Day

Stay up to date with the latest antibody news, subscribe to our newsletter

SYnAbs unique monoclonal antibodies & custom services

2020XII19 SynAbs Short Presentation corp

Adobe Acrobat Document 5.5 MB

Download

Le Fonds européen de développement régional et la Wallonie investissent dans votre avenir.

http://europe.wallonie.be

MENAC - Modifications Epigénétiques des Nucléosomes Associés au Cancer

Le projet MENAC a pour objectif de développer de tests innovants non invasifs pour la détection précoce

de différents types de cancers.

Ce projet réalisé en partenariat par les sociétés Volition et Synabs passe par la création d'anticorps monoclonaux

et la mise au point de nouveaux immuno-essais diagnostiques et théranostiques.

Subvention de 1.990.798€